Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease  by Takeda, Masayuki et al.
CASE REPORT
Successful Treatment with Erlotinib after Gefitinib-Induced
Severe Interstitial Lung Disease
Masayuki Takeda, MD, PhD,* Isamu Okamoto, MD, PhD,* Chihiro Makimura, MD,*
Masahiro Fukuoka, MD, PhD,† and Kazuhiko Nakagawa, MD, PhD*
A 62-year-old woman with an 18-pack-year history ofsmoking was found to have a solitary spiculated lesion
in the right upper lung lobe and multiple pulmonary
nodules on a computed tomography (CT) scan of the chest.
A transcutaneous CT-guided needle biopsy specimen of
the lung revealed adenocarcinoma. She received four cy-
cles of chemotherapy with docetaxel and cisplatin, after
which CT revealed marked tumor shrinkage. During fol-
low-up for 3 months, progressive disease was diagnosed
on the basis of the presence of an enhancement of cortical
sulci on a CT scan of the brain. Mutation analysis of the
lung cancer specimen showed the presence of an exon-19
deletion in the epidermal growth factor receptor (EGFR)
gene, and gefitinib was administered orally at a dose of 250
mg once daily (Figure 1A). After 24 days of gefitinib, the
patient manifested acutely deteriorating dyspnea with fe-
ver and cough. A chest CT scan revealed extensive bilat-
eral ground-glass opacities throughout both lungs (Figure
1B). The results of sputum culture of bacteria or fungi and
general blood tests, including those for fungal antigen and
cytomegalovirus antigen, were negative. The patient had
no prior interstitial lung disease (ILD) or preexisting
collagen-vascular disease. Therefore, we concluded that
the clinical course and imaging results were consistent
with gefitinib-induced ILD. Gefitinib therapy was discon-
tinued, and the treatment with high-dose methylpred-
nisolone was initiated. Given that her symptoms and ra-
diologic findings of gefitinib-induced ILD improved, the
patient was discharged 14 days after discontinuation of
gefitinib. As a result of progression of brain metastasis
soon after discontinuation of gefitinib, whole-brain radia-
tion therapy was delivered. Three months after discontin-
uation of gefitinib, the patient again experienced neuro-
logic progression because of the brain metastasis, and the
development of symptomatic brain metastasis was consid-
ered to be a contraindication for treatment with cytotoxic
agents. After receiving full informed consent for the risk of
recurrent ILD and high mortality rate after the onset of
ILD, we administered erlotinib at a dose of 150 mg/d
(Figure 1C). Nine weeks after the initiation of erlotinib
treatment, a chest CT scan revealed no evidence of ILD
and a reduction in the size of multiple pulmonary meta-
static nodules (Figure 1D). After 11 weeks of erlotinib
treatment, she developed meningeal carcinomatosis with
progressive neurologic symptoms and discontinued erlo-
tinib treatment. ILD has not been identified during the
course of treatment with erlotinib.
DISCUSSION
Gefitinib-induced ILD is the most problematic toxicity,
with an incidence reported to be approximately 4% in Japan
and with about one third of the cases being fatal.1 The
predictive risk factors for ILD development include male sex,
smoking, and the existence of pulmonary fibrosis. The dis-
covery of somatic mutations in the tyrosine kinase domain of
EGFR and of the association of such mutations with a high
response rate to EGFR tyrosine kinase inhibitors (EGFR-
TKIs) such as gefitinib and erlotinib has had a profound
impact on the treatment of advanced non-small cell lung
cancer. Gefitinib-induced severe ILD has been reported only
rarely in EGFR mutation-positive patients, although the prev-
alence of EGFR mutations is estimated to be low in patients
with risk factors for ILD.2
The mechanism of gefitinib-induced ILD has not
been fully elucidated. The previous findings suggest that
inhibition of EGFR-mediated signaling by gefitinib im-
pairs the repair of and thereby exacerbates lung injury.3–5
In the present case, the patient received oral erlotinib (150
mg) daily, which results in a steady-state plasma trough
concentration, that is approximately 3.5 times that for
gefitinib (250 mg), and tumor shrinkage was observed with
no evidence of ILD. These observations suggest that
blockade of the EGFR signaling pathway by EGFR-TKIs
is not necessarily associated with the incidence of drug-
related ILD. Erlotinib and gefitinib share a 4-anilinoquina-
zoline base structure but differ in the substituents attached
to the quinazoline and anilino rings. Minor differences in
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the chemical structure of these compounds may, thus,
influence lung toxicity.
We could successfully manage the patient who had
once developed gefitinib-induced ILD with a full dose of
erlotinib. The present case demonstrated that erlotinib may be
one of the treatment options in such patients when alternative
therapeutic options are limited. Because EGFR TKI-induced
ILD has a high associated mortality, a careful assessment of
clinical symptoms and radiographic findings and informed
consent are needed in this setting.
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FIGURE 1. Chest computed tomography (CT) scans of the patient before (A) and 24 days after initiation of treatment with
gefitinib (B). Bilateral pulmonary infiltrates on the chest CT were apparent on day 24 of gefitinib administration (B). After im-
provement of gefitinib-induced ILD, chest CT scans demonstrated that no ILD was observed in the patients receiving erlotinib
(C and D).
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